Our innovative medical devices, the GILUPI CellCollectors, enable the detection of rare cells directly from the blood of patients. The target cells (e.g. circulating tumor cells - CTCs in oncology) are obtained by in vivo cell isolation. The isolated cells can be characterized at the molecular level. This provides information to the doctors to treat their patients with individual therapies. In oncology, GILUPI’s CellCollector® products enable physicians to monitor the disease of their patients during therapy, and after completion of cancer medication. Besides the use in oncology, it will be possible in the near future to use different devices in other clinical applications. Isolation devices for other rare cells in cardiovascular disease or certain bacteria in severe infection and sepsis are in development.